Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. reports developments in model-informed drug development, combining biosimulation software, technology and services for drug discovery, clinical development and regulatory science. Company news frequently centers on quarterly results, revenue mix between software and services, guidance updates and operating changes following the completed divestiture of its global medical writing and related regulatory services business.
Recurring updates also cover strategic partnerships with drug-development service providers and the use of Certara's Simcyp® Simulator for physiologically based pharmacokinetic modeling. These announcements describe biosimulation applications in clinical pharmacology, new drug applications and regulatory decision-making for biopharmaceutical, academic and agency clients.
Certara, a leader in biosimulation, has appointed Rosemary Crane to its Board of Directors, effective July 21, 2022. This addition increases the board to eleven members. CEO William F. Feehery expressed enthusiasm about Crane's experience in executive leadership and commercialization, which is expected to significantly benefit the company’s growth in the biopharmaceutical sector. Crane brings over 35 years of industry experience, having held leadership positions at several major pharmaceutical companies, including a successful IPO at Epocrates.
Certara, a leader in biosimulation, has appointed Eran Broshy to its Board of Directors, effective July 11, 2022, expanding the board to ten members. Broshy brings over 35 years of experience in healthcare, previously serving as CEO and chairman of inVentiv Health, now part of Syneos Health. His expertise in high-growth healthcare businesses is expected to enhance Certara's strategic direction in drug development. Certara's biosimulation software is used by over 2,000 clients globally, aiming to improve patient outcomes.
Certara, Inc. (Nasdaq: CERT) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call with management is scheduled for 5:00 p.m. ET to discuss these results. Interested investors must register online. An archived webcast will be available on the Certara website.
Certara has launched the Simcyp Discovery Simulator, designed for small molecule drug discovery and translational research. This advanced software enhances early-stage development decisions using physiologically-based pharmacokinetic (PBPK) modeling, aimed at reducing the high failure rate of preclinical drugs. The simulator includes PBPK models for various species and supports early formulation simulations and drug-drug interaction predictions. Certara's commitment to improving drug development processes is underscored by their technological advancements.
Certara announces enhancements to its biosimulation tools, including new versions of its Immunogenicity (IG), Immuno-oncology (IO), and Vaccine Simulators. These innovations aim to improve drug development predictability across various therapeutic areas. Key advancements in the IG Simulator (Version 5.0) allow for more comprehensive evaluation of biologics, while the IO Simulator (Version 4.0) facilitates optimal cancer therapy combinations. Additionally, the Vaccine Simulator addresses dosing strategies for diverse patient populations, contributing to the development of next-generation mRNA vaccines.
Certara, Inc. (Nasdaq: CERT) reported its Q1 2022 financial results, showcasing a 22% revenue growth to $81.6 million compared to Q1 2021. Net income rose to $2.2 million, reflecting a 110% increase. Adjusted EBITDA was $27.7 million, up 16% year-over-year. The company anticipates FY 2022 revenue guidance between $350 - $360 million and adjusted diluted EPS of $0.48 - $0.53. CEO William F. Feehery emphasized the strong demand for their technology-driven services despite some COVID-related delays.
Certara, Inc. (Nasdaq: CERT), a leader in biosimulation, announced participation in several upcoming investor conferences. Key events include the Bank of America 2022 Healthcare Conference on May 10, Citi’s Biopharma Virtual Co-Panel Day on May 18, Jefferies Healthcare Conference from June 8-10, and William Blair’s Annual Growth Stock Conference on June 9. Live webcasts will be available on Certara's investor relations website, with replays accessible for 90 days. Certara specializes in accelerating drug discovery using proprietary biosimulation software.
Certara, Inc. (Nasdaq: CERT) will announce its financial results for Q1 2022 on May 5, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET. Interested investors can participate by calling specific numbers for domestic and international audiences. Certara utilizes proprietary biosimulation software to enhance drug discovery and development, serving over 2,000 clients worldwide.
Certara, Inc. (Nasdaq: CERT) reported Q4 2021 revenue of $75.3 million, a 17% increase from Q4 2020. Excluding Pinnacle 21, revenue grew 7%. The net loss narrowed to $9.7 million from $54.5 million year-over-year, while adjusted EBITDA rose 27% to $28.2 million. For 2021, total revenue reached $286.1 million, up 17% year-over-year. However, 2022 revenue guidance was revised down to $350-$360 million. The company is confident in its mid-teens growth target despite challenges from the Omicron variant.
Certara announces FDA licensing of its Immunogenicity (IG) Simulator, enhancing drug development capabilities. The simulator predicts immune responses in protein therapeutics, crucial for clinical and regulatory decisions. With over five years of rigorous development, Certara aims to address immunogenicity risks, which can significantly impact drug projects. This technology is validated through 20 clinical studies, facilitating virtual patient trials. Certara serves over 2,000 clients globally, underscoring its role as a leader in biosimulation.